- In March 2024, the Bill & Melinda Gates Foundation, in collaboration with UNFPA and PATH, expanded its initiative to improve access to contraceptive implants in Sub-Saharan Africa by funding the distribution of low-cost, quality-assured etonogestrel and levonorgestrel implants. The program aims to increase accessibility for women in underserved regions, reduce supply chain gaps, and support local healthcare worker training. This effort underscores a global commitment to reducing unintended pregnancies through widespread LARC adoption
- In February 2024, Bayer AG announced the successful Phase III clinical trial results of its next-generation levonorgestrel-based subdermal implant designed to offer extended protection up to six years. This marks a significant advancement in implant technology, with the potential to reduce the frequency of reinsertion and improve patient adherence. Bayer’s continued R&D investment reflects its strategic focus on innovation in women’s health and long-acting contraceptive solutions
- In January 2024, Shanghai Dahua Pharmaceutical Co., Ltd. received regulatory approval from China’s National Medical Products Administration (NMPA) for its new two-rod contraceptive implant designed for local and regional use. The approval is expected to boost domestic production and availability of implants in the rapidly expanding Chinese contraceptive market, which is increasingly turning toward LARC methods for population and reproductive health management
- In November 2023, the World Health Organization (WHO), together with Jhpiego and local governments, launched a training and capacity-building program across Southeast Asia to equip primary healthcare providers with implant insertion and removal skills. The initiative aims to strengthen healthcare systems by ensuring safe, effective, and high-quality LARC services across rural and low-resource settings, emphasizing WHO’s commitment to advancing equitable access to reproductive health tools
- In October 2023, Organon & Co. expanded its strategic partnership with local health ministries in Latin America to distribute its branded etonogestrel implant through public health channels. This expansion is focused on addressing unmet contraceptive needs, particularly among adolescents and rural populations. Organon’s initiative also includes education campaigns and healthcare provider support to improve awareness and correct usage of subdermal implants
